Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term induction. Found 42 abstracts

no pagination
Fedele M, Visone R, De Martino I, Palmieri D, Valentino T, Esposito F, Klein-Szanto A, Arra C, Ciarmiello A, Croce CM, Fusco A. Expression of a truncated Hmga1b gene induces gigantism, lipomatosis and B-cell lymphomas in mice. European Journal of Cancer. 2011 Feb;47(3):470-8.   PMCID: not NIH funded
Wang JM, Basagoudanavar SH, Wang XY, Hopewell E, Albrecht R, Garcia-Sastre A, Balachandran S, Beg AA. NF-kappa B RelA Subunit Is Crucial for Early IFN-beta Expression and Resistance to RNA Virus Replication. Journal of Immunology. 2010 Aug;185(3):1720-9.   PMCID: PMC2910841
Gadue P, Gouon-Evans V, Cheng X, Wandzioch E, Zaret KS, Grompe M, Streeter PR, Keller GM. Generation of Monoclonal Antibodies Specific for Cell Surface Molecules Expressed on Early Mouse Endoderm. Stem Cells. 2009 Jan;27(9):2103-13.   PMCID: PMC2890285
Hu W, Ding WJ, Yang HH, Shao MH, Wang BY, Wang JH, Wu SF, Wu SX, Jin LH, Ma CC. Weekly paclitaxel with concurrent radiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma. Radiotherapy and Oncology. 2009 Dec;93(3):488-91.
Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, O'Bryant C, Hariharan S, Diab S, Fox NL, Miceli R, Eckhardt SG. Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study. Journal of Clinical Oncology. 2009 Sep;27(26):4413-21.   PMCID: not NIH funded
Henry LR, Goldberg M, Scott W, Konski A, Meropol NJ, Freedman G, Weiner LM, Watts P, Beard M, McLaughlin S, Cheng JD. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: A phase II report. ANNALS OF SURGICAL ONCOLOGY. 2006 Feb;13(2):214-20.
Liu SX, Abdelrahim M, Khan S, Ariazi E, Jordan VC, Safe S. Aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha in MCF-7 breast cancer cells. BIOLOGICAL CHEMISTRY. 2006 Sep;387(9):1209-13.
Masters GA, Li SG, Dowlati A, Madajewicz S, Langer C, Schiller J, Johnson D. A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) in patients with advanced non-small cell lung cancer: An Eastern Cooperative Oncology Group Study (E1501). JOURNAL OF THORACIC ONCOLOGY. 2006 Sep;1(7):673-8.
Roberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, Honeycutt C, Thune R, Padavic-Shaller K, Carter WH, Ramakrishnan V, Murgo AJ, Grant S. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (Non-Hodgkin's) lymphoma. CLINICAL CANCER RESEARCH. 2006 Oct;12(19):5809-16.
Yao KS, Shida S, Selvakumaran M, Zimmerman R, Simon E, Schick J, Haas NB, Balke M, Ross H, Johnson SW, O'Dwyer PJ. Macrophage migration inhibitory factor is a determinant of hypoxia-induced apoptosis in colon cancer cell lines. Clinical Cancer Research. 2005 Oct 15;11(20):7264-72.
Finegan MM, Han AC, Edelson MI, Rosenblum NG. p16 expression in squamous lesions of the female genital tract. Journal of Molecular Histology. 2004 Feb;35(2):111-4.
O'Donnell MR, Appelbaum FR, Baer MR, Carabasi MH, Coutre SE, Erba HP, Estey E, Glenn MJ, Kraut EH, Maslak P, Millenson M, Miller CB, Saba HI, Stone R, Tallman MS. NCCN Practice Guidelines for acute myelogenous leukemia. Oncology-New York. 2000 Nov;14(11A):53-61.
O'Dwyer PJ, Szarka C, Brennan JM, Laub PB, Gallo JM. Phramacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose. Clinical Cancer Research. 2000 Dec;6(12):4692-6.
Sigal LJ, Rock KL. Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)- dependent and -independent pathways of antigen presentation. Journal of Experimental Medicine. 2000 Oct 16;192(8):1143-50.
Yin ZM, Ivanov VN, Habelhah H, Tew K, Ronai Z. Glutathione S-transferase p elicits protection against H2O2- induced cell death via coordinated regulation of stress kinases. Cancer Research. 2000 Aug;60(15):4053-7.
Matsuda T, Terashima I, Matsumoto Y, Yabushita H, Matsui S, Shibutani S. Effective utilization of N-2-ethyl-2 '-deoxyguanosine triphosphate during DNA synthesis catalyzed by mammalian replicative DNA polymerases. Biochemistry. 1999 Jan 19;38(3):929-35.
Miknyoczki SJ, Chang H, Klein-Szanto A, Dionne CA, Ruggeri BA. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clinical Cancer Research. 1999 Aug;5(8):2205-12.
Miknyoczki SJ, Dionne CA, Klein-Szanto AJ, Ruggeri BA. The novel Trk receptor tyrosine-kinase inhibitor CEP-701 (KT- 5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness. In: Cell and Molecular Biology of Pancreatic Carcinoma: Recent Developments in Research and Experimental Therapy. 1999. p. 252-62.
Ranganathan S, Ciaccio PJ, Walsh ES, Tew KD. Genomic sequence of human glyoxalase-I: analysis of promoter activity and its regulation. Gene. 1999 Nov 15;240(1):149-55.
Kelsall SR, Mintz B. Metastatic cutaneous melanoma promoted by ultraviolet radiation in mice with transgene-initiated low melanoma susceptibility. Cancer Research. 1998 Sep 15;58(18):4061-5.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term induction

induction cancer chemotherapy cell-lines gene-expression expression radiation-therapy gene carcinoma growth dendritic cells transcription enhanced expression activated protein-kinase p53 carboplatin Oncology damage adenocarcinoma trial agents particulate antigens activation potential role irradiation mechanisms embryonic stem-cells human colon factor gene transactivation tumor radioresponse selective AhR modulators bisphenol-a mutations Monoclonal antibodies ESC-EB-Differentiation antigens-Differentiation gemcitabine blood-samples phase-iii marrow transplantation colony-stimulating factor vivo transfection visceral-endoderm low-grade lymphoma azoxymethane chemoradiotherapy tyrosinase double-stranded-rna dna- protein-kinase-c male f344 rats bone- transgenic mice esophageal cancer potential application transcription factors apoptosis interferon regulatory factor-3 hmgi-c gene randomized-trial tumorigenesis signal-transduction Biochemistry & Molecular Biology Lymphoma Adipogenesis-Experimental animal models-Oncogene-E2F1-High Mobility Group proteins zinc- acute promyelocytic leukemia diabetes family natural-killer-cell preoperative chemoradiation cellular apo2l lung-cancer tumor-associated angiogenesis apoptosis-inducing ligand bone-marrow cells enzymes cytotoxic agent bryostatin-1 oncology-group murine melanomas insulin benign mesenchymal tumors repair definitive endoderm drug model Chemoradiotherapy T surgery p16(ink4a) toxicity prostate-cancer cells lymphocytes dna-based immunization cloning hydroxydeoxyguanosine phorbol ester aromatic-hydrocarbons exisulind estrogenicity Nasopharyngeal carcinoma oxidoreductase Locally advanced major histocompatibility insulin-response element transformation neck oltipraz invitro AhR first remission mhc class-i novel agent malignant skin melanoma trail tissues complex mouse model methylglyoxal hematopoietic progenitor cells responsiveness clonogenic response peripheral lymphocytes binding therapy high-dose cytarabine death receptors decoy receptors adapter protein modulation supralethal growth-factor receptor arsenic trioxide 8- human monoclonal-antibody diabetic rats 3 2-7-8-tetrachlorodibenzo-para-dioxin pathways paclitaxel neoadjuvant pattern proteins factor mif hamster ovary cells cross-talk radiotherapy phase II trial protein acetaldehyde p300
Last updated on Tuesday, July 03, 2018